| PAD Consequences |
4 |
| Consequences of Critical Limb Ischemia |
5 |
| Consequences of First Stroke |
5 |
| Percentage of Patients with Intermittent Claudication |
6 |
| Cause of Death in PAD |
8 |
| Five-Year All-Cause Mortality for Selected Diseases |
9 |
| Ten-Year Mortality for PAD by Disease Severity Compared to Survivors
of First Heart Attack |
9 |
| Percentage of PAD Patients with Coronary Artery Disease (CAD) or Cerebrovascular Disease (CVD) |
10 |
| Ankle Brachial Index (ABI) |
10 |
| Five-Year Mortality and Incidence of Non-Fatal MI or Stroke |
11 |
| ABI and PAD Severity and Symptoms |
12 |
| Treatment of PAD |
13 |
|
Revascularization |
14 |
| Type I Disease |
17 |
| Type II Disease |
18 |
| Type III Disease |
18 |
| PAD - Disease and Lesion Classification Systems |
19 |
| Definitions of Interventional Success |
21 |
| Advantages and Disadvantages of Bypass Surgery |
24 |
| Indications for Bypass Surgery |
24 |
| Bypass Surgery Recommended for These Types of Lesions |
25 |
| Bypass Surgery - Outcome Measurements |
26 |
|
Bypass Surgery - Comparison of Five-Year Patency by Graft Type Autologous (AVG) and Synthetic (SVG) |
27 |
| Complications of Peripheral Bypass Surgery |
27 |
| Types of Bypass Grafts |
28 |
| Graft Manufacturers |
29 |
| Endovascular Treatments For Peripheral Arterial Disease |
32 |
| Peripheral Angioplasty |
33 |
| Variables in Successful PTA |
34 |
| Complications of PTA |
34 |
| Antiplatelets |
35 |
| U.S. Peripheral Endovascular Market |
39 |
| Stent Complications |
40 |
|
Atherectomy Devices |
41 |
| Aortoiliac Disease |
43 |
| Aortoiliac Disease - Choice of PTA or Surgery |
44 |
| PTA Preferred Treatment For These Iliac Lesions (TASC Type A) |
45 |
| PTA May Be Used For These Iliac Lesions (TASC Type B/C) |
45 |
| Surgery Recommended Treatment For These Iliac Lesions (TASC Type D) |
45 |
| Aortoiliac Revascularization Comparison of PTA and Bypass Surgery |
46 |
| Comparison of PTA and Stents - Aortoiliac Procedures |
47 |
| Peripheral Balloon-Expandable Stents |
51 |
| Peripheral Self-Expanding Stents |
52 |
| CRISP US Study - Comparison of Selected Results - SMART and Wallstent |
54 |
|
Peripheral Covered Stents................. 55 |
55 |
| Femoropopliteal Disease with SFA Occlusion |
59 |
| Characteristics Femoropopliteal Disease |
60 |
| Optimal Conditions for Successful Femoral PTA |
60 |
| Femoropopliteal and Aortoiliac PTA - Comparison of Success and Complications By Lesion Type |
61 |
| Comparison of PTA and Bypass Femoropopliteal |
63 |
| Mode of Failure, Treatment Options and Cost For Femoropopliteal Bypass Surgery and PTA |
64 |
| Indications for Femoropopliteal Stents |
67 |
| Restenosis in Femoropopliteal Stenting |
67 |
| Stents in The SFA Patency and Restenosis Selected Results of Nine Studies 1989 - 1997 |
69 |
| Femoropopliteal Comparison of Bypass Surgery and PTA with Stents Results of Selected Studies |
70 |
| Infrainguinal Self-Expanding Stents |
73 |
| Comparison of Restenosis Rates Between Stainless Steel and Nitinol Stents in the Femoropopliteal Arteries |
75 |
| Femoropopliteal Self-Expanding Nitinol Stents Early Results of Selected Studies In Stenoses and Occlusions |
76 |
| Femoropopliteal Stent-Grafts Results of Three Studies Employing the Hemobahn Endoprothesis |
79 |
| Peripheral Drug-Eluting Stents Published Clinical Trials |
81 |
| New Devices for Crossing CTOs Peripheral Results |
85 |
| Tibioperoneal Disease Accompanied by SFA Stenosis |
90 |
| Limited Indications for Below-the-Knee PTA |
90 |
| Tibial PTA Success and Complication Rates |
90 |
| Infrapopliteal PTA and Surgery For Critical Limb Ischemia Selected Outcomes |
92 |
| Critical Limb Ischemia - Limb Salvage Rates - Comparison of Selected Endovascular Technologies |
95 |
| Critical Limb Ischemia Consequences of Treatment Options in Poor Surgical Candidates |
98 |
| Critical Limb Ischemia Cost Comparison of Amputation and Revascularization |
100 |
| Estimated Number of People with PAD 2000 - 2020 |
101 |
| Primary and Revision Peripheral Bypass Procedures 1983-2000 (Non-Federal and VA Hospitals) |
103 |
| Primary Peripheral Bypass Procedures 1983-2000 (Non-Federal and VA Hospitals) |
104 |
| Peripheral Interventional Procedures 1983-2000 Aortoiliac Bypass (AI-BP), Infrainguinal Bypass (II-BP) and Angioplasty (PTA) |
105 |
| Estimated Percentage of Peripheral Bypass Procedures Performed By Indication 1985 and 2000 |
107 |
| Estimated Total Amputations Related to Peripheral Disease 1983-2000 |
108 |
| 2000 U.S. PAD Market Potential For Interventional Therapy (IT) By Disease Severity |
110 |
| 2000 U.S. PAD Market Potential For Bypass (BP) and Endovascular Therapy (ET) By Disease Severity |
111 |
| 2000 U.S. PAD Market Potential For Bypass Surgery (BP) By Disease Severity (Limbs) |
112 |
| 2000 U.S. PAD Market Potential For Endovascular Therapy (ET) By Disease Severity (Limbs) |
113 |
| 2000-2020 U.S. PAD Market Potential For Bypass Surgery (BP) and Endovascular Therapy (ET) As the Population Ages (Limbs) |
114 |
| 2003 U.S. PAD Market for Bypass (BP) - Current Market Compared to Potential Market (Procedures) |
115 |
| 2000-2010 Projected Growth of Current Bypass Market and Potential Market If Percentage of Patients Diagnosed Increases to 30% |
116 |
| 2000-2010 Projected Growth of Current Bypass Market and Potential Market If Percentage of Patients Diagnosed Increases to 35% |
117 |
| PAD 2003 U.S. PAD Market for Endovascular Therapy (ET) - Current Market Compared to Potential Market (Procedures) |
118 |
| 2000-2010 Projected Growth of Current Endovascular Market and Potential Market If Percentage of Patients Diagnosed Increases to 30% |
119 |
| 2000-2010 Projected Growth of Current Endovascular Market and Potential Market If Percentage of Patients Diagnosed Increases to 35% |
120 |
| 2003 U.S. PAD Market Potential For Primary and Redo Bypass Surgery (BP) By Disease Severity (Limbs) |
121 |
| 2000-2020 U.S. PAD Market Potential For Primary and Redo Bypass Surgery By Disease Severity (Limbs) |
122 |
| 2003 U.S. PAD Market Potential For Primary and Redo Endovascular Therapy (ET) By Disease Severity (Limbs). |
123 |
2000-2020 U.S. PAD Market Potential For Primary and Redo Endovascular Therapy (ET) By Disease Severity (Limbs) |
124 |
